Protocol Ledger

NCT03375307 · Phase II · ACTIVE NOT RECRUITING

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Interventional Phase II clinical trial protocol NCT03375307 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-03 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03375307
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03375307
Protocol FieldVerified Registry Value
NCT IdentifierNCT03375307
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2020-11-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI